Imatinib alone and in combination for chronic myeloid leukemia

  • Druker B
  • 14

    Readers

    Mendeley users who have this article in their library.
  • 93

    Citations

    Citations of this article.

Abstract

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms. Copyright 2003, Elsevier Science (USA). All rights reserved.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Brian J. Druker

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free